Almoosa Health (4018) Fundamentals 2026 — P/E 24.8x, Revenue Analysis | SniperIQ
Almoosa Health (4018) is a SA-listed Healthcare company in Medical - Care Facilities with a market capitalization of SAR 5.2B, trading at SAR 117.00 on the SAU. This SniperIQ fundamentals page covers Almoosa Health's valuation (P/E 24.8x, P/B 2.7x), profitability (net margin 14.5%), revenue (SAR 1.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Almoosa Health's market cap?
Almoosa Health (4018) has a market capitalization of approximately SAR 5.2B, trading at SAR 117.00 on the SAU. Market cap moves with the live share price.
What is Almoosa Health's P/E ratio?
Almoosa Health's trailing twelve-month P/E ratio is 24.8x, with a price-to-book (P/B) of 2.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Almoosa Health?
Almoosa Health runs a net profit margin of 14.5%, a gross margin of 31.0%, and an operating margin of 13.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Almoosa Health generate?
Almoosa Health reported revenue of SAR 1.4B for fiscal year 2025, with net income of SAR 237M and earnings per share (EPS) of 5.36. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Almoosa Health pay a dividend?
Almoosa Health offers a trailing dividend yield of about 1.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Almoosa Health financially healthy?
Almoosa Health carries a debt-to-equity ratio of 0.50x and a current ratio of 1.71x, with a market beta of 0.35. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Almoosa Health a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Almoosa Health (4018) the key facts are: market cap SAR 5.2B, P/E 24.8x, revenue SAR 1.4B, 52-week range 110-212. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Almoosa Health's full fundamentals live
Get Almoosa Health's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.